REMAIN-1: A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Pivotal Study to Assess the Efficacy of Revita Duodenal Mucosal Resurfacing (DMR) on Body Weight Maintenance in Participants with Obesity and Who Have Achieved at Least 15% Weight Loss on Tirzepatide Obesity Pharmacotherapy
-
Enrollment
This study is currently enrolling. -
Research Area
Translational Research -
Location
-
Principal Investigator
-
Sponsor
Fractyl Health
REMAIN-1 The purpose of this research is to see if doing a procedure that temporarily removes the lining of your duodenum (first part of your small intestine) can help you keep from regaining weight after you stop your tirzepatide (ZepboundTM).
Enrollment Form
This study is currently enrolling.